Pyxis Oncology (PYXS) Director Jakob Dupont Receives 46,000-Share Award

What Happened Jakob Dupont, a director of Pyxis Oncology, received a grant of 46,000 derivative shares (award) on August 20, 2026. The award was reported at a $0.00 acquisition price (i.e., no cash paid at grant). This is a compensation/award transaction rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-20; reported filing date: 2026-08-20 (appears timely).
• Shares/units granted: 46,000 (derivative award); reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The award vests in equal monthly installments through October 31, 2026, subject to Dupont’s continued service.
• Transaction type: A = Award/Grant (derivative securities). No 10b5-1, tax-withholding, or sale activity noted in this report.

Context Director awards like this are commonly used for board compensation and do not indicate an immediate purchase/sale or short-term market view. Because these are derivative awards subject to future vesting, the economic interest will only accrue as the grants vest; there is no immediate sale or cash proceeds associated with this filing.